- Home
- BRW vs CRMD Comparison
BRW vs CRMD Comparison
Compare BRW & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRW
- CRMD
- Stock Information
- Founded
- BRW 1987
- CRMD 2006
- Country
- BRW United States
- CRMD United States
- Employees
- BRW N/A
- CRMD N/A
- Industry
- BRW Trusts Except Educational Religious and Charitable
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- BRW Finance
- CRMD Health Care
- Exchange
- BRW Nasdaq
- CRMD Nasdaq
- Market Cap
- BRW 313.9M
- CRMD 279.7M
- IPO Year
- BRW N/A
- CRMD 2010
- Fundamental
- Price
- BRW $7.45
- CRMD $11.20
- Analyst Decision
- BRW
- CRMD Strong Buy
- Analyst Count
- BRW 0
- CRMD 5
- Target Price
- BRW N/A
- CRMD $12.60
- AVG Volume (30 Days)
- BRW 222.1K
- CRMD 946.7K
- Earning Date
- BRW 01-01-0001
- CRMD 11-12-2024
- Dividend Yield
- BRW 15.59%
- CRMD N/A
- EPS Growth
- BRW N/A
- CRMD N/A
- EPS
- BRW N/A
- CRMD N/A
- Revenue
- BRW N/A
- CRMD $806,119.00
- Revenue This Year
- BRW N/A
- CRMD N/A
- Revenue Next Year
- BRW N/A
- CRMD $206.77
- P/E Ratio
- BRW N/A
- CRMD N/A
- Revenue Growth
- BRW N/A
- CRMD 2107.40
- 52 Week Low
- BRW $7.15
- CRMD $2.57
- 52 Week High
- BRW $8.30
- CRMD $11.22
- Technical
- Relative Strength Index (RSI)
- BRW 52.51
- CRMD 87.53
- Support Level
- BRW $7.32
- CRMD $9.67
- Resistance Level
- BRW $7.44
- CRMD $10.66
- Average True Range (ATR)
- BRW 0.08
- CRMD 0.48
- MACD
- BRW -0.01
- CRMD 0.10
- Stochastic Oscillator
- BRW 52.00
- CRMD 99.38
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund t is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.